荧光原位杂交检测乳腺癌Her-2基因的表达及其意义

目的探讨荧光原位杂交技术检测乳腺癌Her-2基因的表达及其临床应用。方法应用荧光原位杂交技术（FISH）和免疫组化技术（IHC）分别检测了50例乳腺癌患者手术切除标本的Her-2基因和Her-2蛋白的表达。结果 50例乳腺癌患者组织中Her-2基因FISH阳性率为44%（22/50）;Her-2蛋白IHC阳性（＋～＋＋＋）率为54%（27/50）;两者同时为阴性的符合率为86.96%。当IHC阳性（＋）时与FISH结果的符合率为40%（4/10）I;HC阳性（＋＋）时与FISH结果的符合率为81.81%（9/11）I;HC阳性（＋＋＋）时与FISH结果的符合率为100%。在肿块最大径小于2cm病例中,Her-2基因FISH阳性率为18.75%（3/16）;在大于2cm的病例中,Her-2基因FISH阳性率为55.88%（19/34）,两者间差异显著;在未发生淋巴结转移的患者中Her-2基因FISH阳性率为34.28%（12/35）,而在有淋巴结转移的患者中Her-2基因FISH阳性率为66.67%（10/15）,两者间差异有统计学意义（χ2=4.47,P〈0.05）。结论 IHC检测Her-2阴性或强阳性（＋＋＋）时与FISH检测结果符合率较高,而当IHC为阳性（＋～＋＋）时需结合FISH实验以确定Her-2基因的表达状态;Her-2基因的表达与肿瘤长径的大小、腋淋巴结的转移呈正相关。

Clinical application of fluorescence in situ hybridization for detection of Her-2 gene in breast cancer patients

Objective To detect the expression of Her-2 gene in breast carcinoma patients by fluorescence in situ hybridization(FISH).Methods Her-2 gene and Her-2 protein expression in 50 breast carcinoma cases were detected by FISH and immunohistochemistry(IHC) respectively.Results The positive rate of Her-2 gene detected by FISH was 44%(22/50),that of Her-2 protein detected by IHC was 54%(27/50) in 50 breast carcinoma cases,and the negative coincidence rate was 86.96%.The Her-2 gene positive rate detected by FISH was...